![[FROM LEFT] Claudia Popp, Olga Tkachenko and Marta Carnielli](https://ds982gbwnvyso.cloudfront.net/Pictures/274x183/4/4/1/441_5m4a4767_toprasymposium2022_day3_20221019_816643.jpg)
Presentation of immunogenicity-related information in regulatory dossiers
The purpose of this continuing professional development supplement is to explain how an integrated summary report can be created to consolidate the information required for assessment of immunogenicity-related risks of different types of biopharmaceuticals.
This is member-only content
To read this article, SIGN IN NOW if you are a TOPRA member.
Not a TOPRA member yet?
Join now to get access to:
- Features and specialist articles
- CPD supplements
- Comprehensive archive
Not sure yet? Read one of our free editorials to see what you’re missing out on!
The Organisation for Professionals in Regulatory Affairs
- Issues
- Contact us
- Topics A-Z
- Contributors A-Z
- © 2023 Regulatory Rapporteur